Meningitis is a substantial contributor to mortality in children younger than 5 years of age in low- and middle-inc ...

The CTAR Programme is aimed at identifying and developing first-in-class therapeutics for infections caused by ...

Xacduro is the only antimicrobial agent specifically developed for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It has been approved in the United States and in mainland China ...

Zai Lab and Pfizer have partnered for the commercialization of Xacduro (sulbactam-durlobactam) in China, targeting carbapenem ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

Zai Lab and Pfizer have entered a strategic collaboration to commercialise XACDURO (sulbactam-durlobactam), a new ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Zai Lab and Pfizer Inc. are teaming up in China to fight the deadly carbapenem-resistant Acinetobacter baumannii (CRAB) infection with novel antibacterial drug Xacduro (sulbactam-durlobactam). Through ...

Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for ...

Antibacterial drugs are important for treating infections. But increasingly, bacterial resistance to current drugs -; so they don't work well, or even at all -; means new ones are urgently needed.

Antibacterial drugs are important for treating infections. But increasingly, bacterial resistance to current drugs—so they ...

In a significant advancement, a modified darobactin compound has shown promise in treating drug-resistant bacterial infections in animal models, offering a potential new weapon against pathogens like ...